Recursion, a TechBio company decoding biology to improve lives, and Google Cloud have announced an expanded collaboration leveraging Google Cloud’s technologies to support Recursion’s drug discovery platform.
 
This strategic partnership comprises exploring generative AI capabilities, including Gemini models, to support the RecursionOS, drive improved search and access with BigQuery, and help scale compute resources. In addition, Recursion will also explore making some of its AI models available on Google Cloud. The enriched partnership supports Recursion’s ongoing effort to tackle the biopharmaceutical industry’s critical challenge of slow and costly drug development by reducing the time and cost involved in bringing new therapies to patients—ushering in a new era of accessible and affordable healthcare globally.
 
By streamlining the drug development process and increasing its success rate, Recursion seeks to bring new, life-saving treatments to patients faster and more affordably.
 
“Our partnership with Google Cloud supports the acceleration of our research with a goal of bringing new and better treatments to patients more efficiently,” said Chris Gibson, co-founder and CEO, Recursion. “We are pleased to have Google Cloud help us  continue to push the boundaries of drug discovery and the development of new treatments for patients faster than ever before using their cloud infrastructure.”
 
The two companies have a history of successful collaboration, working together for more than six years. To date, Google Cloud has provided infrastructure and services, enabling Recursion to manage its biology and chemistry datasets, and complex computations involved in extracting insights from this data using its foundation models. This application of AI has already accelerated Recursion’s drug discovery, increasing the speed and lowering the cost of IND studies.
 
“We can help unlock the complexities of biology through the use of cutting-edge AI tools,” said Thomas Kurian, CEO, Google Cloud. “Through our partnership with Recursion, we’re supporting the discovery of novel therapeutics by combining Recursion’s vast biological dataset and its own AI capabilities with the opportunity to explore our advanced AI and other technologies. Our goal is for this to not only deepen our scientific understanding, but also pave the way for a future where new treatments for complex diseases are developed faster and more efficiently for patients worldwide.”